Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Standard Biotools (LAB) over the last 14 years, with Q3 2025 value amounting to $65.5 million.

  • Standard Biotools' Short-term Investments fell 5793.7% to $65.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.5 million, marking a year-over-year decrease of 5793.7%. This contributed to the annual value of $126.1 million for FY2024, which is 9962.65% up from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' Short-term Investments is $65.5 million, which was down 5793.7% from $78.5 million recorded in Q2 2025.
  • Standard Biotools' 5-year Short-term Investments high stood at $175.2 million for Q1 2024, and its period low was $40.9 million during Q1 2023.
  • Over the past 4 years, Standard Biotools' median Short-term Investments value was $107.2 million (recorded in 2025), while the average stood at $102.5 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first plummeted by 6063.39% in 2023, then soared by 32869.55% in 2024.
  • Standard Biotools' Short-term Investments (Quarter) stood at $84.5 million in 2022, then decreased by 25.2% to $63.2 million in 2023, then skyrocketed by 99.63% to $126.1 million in 2024, then crashed by 48.09% to $65.5 million in 2025.
  • Its last three reported values are $65.5 million in Q3 2025, $78.5 million for Q2 2025, and $107.2 million during Q1 2025.